TEM-103/IRT-28 beta-lactamase, a new TEM variant produced by Escherichia coli BM4511.
Clinical isolate Escherichia coli BM4511 was resistant to broad-spectrum penicillins in the presence or in the absence of beta-lactamase inhibitors but remained susceptible to cephalosporins. Resistance was due to production of a new TEM-type beta-lactamase, designated TEM-103/IRT-28, characterized by the Arg(275)Leu substitution and encoded by the ca. 62-kb pIP845 conjugative plasmid of the IncI1 incompatibility group.
Alonso
Rodrigo
R
Unité des Agents Antibactériens, Institut Pasteur, 75724 Paris Cedex 15, France.
Gerbaud
Guy
G
Galimand
Marc
M
Courvalin
Patrice
P
D000368:Aged; D000369:Aged, 80 and over; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology; D004269:DNA, Bacterial / Q000235:genetics; D004359:Drug Therapy, Combination / Q000494:pharmacology; D004926:Escherichia coli / Q000201:enzymology* / Q000235:genetics; D004927:Escherichia coli Infections / Q000382:microbiology; D029968:Escherichia coli Proteins / Q000235:genetics; D005260:Female; D006801:Humans; D010403:Penicillin Resistance; D013530:Surgical Wound Infection / Q000382:microbiology; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000235:genetics
D004269:DNA, Bacterial; D029968:Escherichia coli Proteins; D019980:Amoxicillin-Potassium Clavulanate Combination; D001618:beta-Lactamases; C472387:beta-lactamase TEM-103, E coli